ArticleProceedings of the National Academy of Sciences of the United States of America2026
Design of solubly expressed miniaturized SMART MHCs.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A miniaturized MR1 metabolite display system with native-like protein features.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
William L WhiteDepartment of Bioengineering, University of Washington, Seattle, WA 98195.ORCID 0009-0004-0041-2125
Hua BaiInstitute for Protein Design, School of Medicine, University of Washington, Seattle, WA 98195.
Chan Jhong KimInstitute for Protein Design, School of Medicine, University of Washington, Seattle, WA 98195.
Kevin M JudeDepartment of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305.ORCID 0000-0002-3675-5136
Renhua SunScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute and Division of Infectious Diseases, Karolinska University Hospital, Stockholm 171 77, Sweden.ORCID 0000-0002-8203-4946
Laura GuerreroDepartment of Bioengineering, Stanford University, Stanford, CA 94305.ORCID 0000-0003-4770-100X
Xiao HanScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute and Division of Infectious Diseases, Karolinska University Hospital, Stockholm 171 77, Sweden.ORCID 0000-0003-0879-4119
Xiaojing ChenDepartment of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305.
Apala ChaudhuriCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0000-0003-2669-850X
Julia E BonzaniniDepartment of Bioengineering, University of Washington, Seattle, WA 98195.ORCID 0009-0004-0860-9678
Yi SunCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104.
Amarachi E OnwukaCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0000-0002-6708-4005
Nan WangDepartment of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305.ORCID 0000-0001-6840-5336
Chunyu WangDepartment of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305.
Per-Åke NygrenInstitute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109.ORCID 0000-0003-4214-6991
Xinting LiInstitute for Protein Design, School of Medicine, University of Washington, Seattle, WA 98195.
Inna GoreshnikInstitute for Protein Design, School of Medicine, University of Washington, Seattle, WA 98195.
Aza AllenInstitute for Protein Design, School of Medicine, University of Washington, Seattle, WA 98195.
Paul M LevineInstitute for Protein Design, School of Medicine, University of Washington, Seattle, WA 98195.
Hao Yuan KuehDepartment of Bioengineering, University of Washington, Seattle, WA 98195.ORCID 0000-0001-6272-6673
Michael C JewettDepartment of Bioengineering, Stanford University, Stanford, CA 94305.
Nikolaos G SgourakisCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104.ORCID 0000-0003-3655-3902
Adnane AchourScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute and Division of Infectious Diseases, Karolinska University Hospital, Stockholm 171 77, Sweden.ORCID 0000-0003-0432-710X
K Christopher GarciaDepartment of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305.ORCID 0000-0001-9273-0278
David BakerInstitute for Protein Design, School of Medicine, University of Washington, Seattle, WA 98195.ORCID 0000-0001-7896-6217
Funding
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Sean McSweeney · 2019 to 2026
$38.6MStructural correlates of T cell receptor signalingR01AI103867 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2014 to 2026
$5.3MAn integrative structural biology approach to understanding metabolite recognition by cellular receptorsR35GM125034 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SGOURAKIS, NIKOLAOS · 2017 to 2025
$4.7MNextGen - CHOPOT2CA278687 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2022 to 2026
$2.7MEngineering synthetic feedback control in T cell signaling for anti-tumor immunityR01CA282512 · NCI · YALE UNIVERSITY · PI Hao Yuan Kueh · 2024 to 2026
$1.9MMATCHMAKERSOT2CA297288 · NCI · UNIVERSITY OF WASHINGTON · PI DAVID BAKER · 2024 to 2026
$1.2MMATCHMAKERS: SOLVING TCR RECOGNITION AND DESIGN VIA INTEGRATED HIGH-THROUGHPUT SCREENING, STRUCTURAL, FUNCTIONAL, AND COMPUTATIONAL APPROACHESOT2CA297242 · NCI · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2024 to 2026
$1.1MMATCHMAKERS - Solving TCR recognition and design via integrated high-throughput screening, structural, functional, and computational approachesOT2CA297575 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Nikolaos Sgourakis · 2024 to 2026
$1.0MNext generation platforms for interrogating TCR specificityR33CA302206 · NCI · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2025 to 2026
$737kInput encoding in T-cell receptor signalingR21EB027327 · NIBIB · UNIVERSITY OF WASHINGTON · PI KUEH, HAO YUAN · 2019 to 2021
$622kBill & Melinda Gates Foundation INV-010680Cancerfonden (Swedish Cancer Society) 24 3775 Pj O1 HCancer Research UK (CRUK) CGCATF-2021/100002Cancer Research UK (CRUK) CGCATF-2023/100006Cancer Research UK (CRUK) CGCATF-2023/100008DOD | Defense Threat Reduction Agency (DTRA) HDTRA1-21-1-0038DOD | USA | AFC | CCDC | ARO | Life Sciences Division, Army Research Office (Life Sciences Division ARO) W911NF-23-1-0334DOE | SC | Biological and Environmental Research (BER) BO070Gates Foundation INV-010680HHS | NIH | National Cancer Institute (NCI) 1-R33 CA302206-01HHS | NIH | National Cancer Institute (NCI) CA278687-01HHS | NIH | National Cancer Institute (NCI) OT2CA297242HHS | NIH | National Cancer Institute (NCI) OT2CA297288HHS | NIH | National Cancer Institute (NCI) R01CA282512HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 5R01AI103867-08HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB) R21EB027327HHS | NIH | National Institute of General Medical Sciences (NIGMS) P30GM133893Insamlingsstiftelsen Cancer- och Allergifonden (Cancer and Allergy Fund) 11338Ludwig Institute for Cancer Research (LICR) N/AMark Foundation For Cancer Research (Mark Foundation) N/ANCI NIH HHS OT2 CA278687NCI NIH HHS OT2 CA297242NCI NIH HHS OT2 CA297288NCI NIH HHS OT2 CA297575NCI NIH HHS R01 CA282512NCI NIH HHS R33 CA302206NIAID NIH HHS R01 AI103867NIBIB NIH HHS R21 EB027327NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R35 GM125034NSF | NSF Graduate Research Fellowship Program (GRFP) DGE-1656518Stiftelsen Konung Gustaf V:s Jubileumsfond (King Gustaf V's Jubilee Foundation) 244092Vetenskapsrådet (VR) 2021-05061Yosemite Fund N/A
Abstract
The precise recognition of specific peptide-major histocompatibility complex (pMHC) complexes by T cell receptors (TCRs) plays a key role in infectious disease, cancer, and autoimmunity. A critical step in many immunobiological studies is the identification of T cells expressing TCRs specific to a given pMHC antigen. However, the intrinsic instability of empty class-I MHCs limits their soluble expression in
Indexed as
Histocompatibility Antigens Class IReceptors, Antigen, T-Cellbeta 2-MicroglobulinEscherichia coliHumansPeptidesProtein BindingSolubilitybeta 2-MicroglobulinHistocompatibility Antigens Class IPeptidesReceptors, Antigen, T-Cellmajor histocompatibility complexprotein designsoluble expressionT cell receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.